Estilo A - Search Results

1

Using an Automated Algorithm to Identify Potential Drug-Induced Liver Injury Cases in a Pharmacovigilance Database.

Pineda Salgado L, Gupta R, Jan M, Turkoglu O, Estilo A, George V, Rahman MI. Pineda Salgado L, et al. Among authors: estilo a. Adv Ther. 2021 Sep;38(9):4709-4721. doi: 10.1007/s12325-021-01856-x. Epub 2021 Jul 28. Adv Ther. 2021. PMID: 34319549 Free PMC article.

2

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.

Hey-Hadavi J, Seekins D, Palmer M, Coffey D, Caminis J, Abdullaev S, Patwardhan M, Tyler H, Raheja R, Stanley AM, Pineda-Salgado L, Bourdet DL, Andrade RJ, Hayashi PH, Dimick-Santos L, Rockey DC, Estilo A. Hey-Hadavi J, et al. Among authors: estilo a. Drug Saf. 2021 Jun;44(6):619-634. doi: 10.1007/s40264-021-01051-5. Epub 2021 Mar 16. Drug Saf. 2021. PMID: 33725335 Free PMC article. Review.

3

Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.

Estilo A, McCormick L, Rahman M. Estilo A, et al. Adv Ther. 2021 Dec;38(12):5721-5736. doi: 10.1007/s12325-021-01947-9. Epub 2021 Oct 25. Adv Ther. 2021. PMID: 34693505 Free PMC article.

4

Evaluating the impact of a Risk Evaluation and Mitigation Strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease.

Estilo A, Tracy L, Matthews C, Riggen M, Stemhagen A, Wilt T, Krakovich A, Jones-Burton C, George V, McQuade R, Rahman M. Estilo A, et al. Clin Kidney J. 2022 Mar 11;15(8):1553-1561. doi: 10.1093/ckj/sfac076. eCollection 2022 Aug. Clin Kidney J. 2022. PMID: 36824061 Free PMC article.

5

Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use.

Marquez L, Raheja R, Chan-Liston M, Marcinak J, Estilo A, Pineda Salgado L, Jiang J, Chang C, Beninger P. Marquez L, et al. Among authors: estilo a. Drug Saf. 2024 Jan;47(1):1-22. doi: 10.1007/s40264-023-01360-x. Epub 2023 Oct 24. Drug Saf. 2024. PMID: 37874451 Review.

6

Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Lee J, Hoke ME, Estilo A, Sergeyeva O. Torres VE, et al. Among authors: estilo a. Clin J Am Soc Nephrol. 2020 Dec 31;16(1):48-58. doi: 10.2215/CJN.10250620. Epub 2020 Dec 29. Clin J Am Soc Nephrol. 2020. PMID: 33376102 Free PMC article. Clinical Trial.

7

Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.

Alpers DH, Lewis JH, Hunt CM, Freston JW, Torres VE, Li H, Wang W, Hoke ME, Roth SE, Westcott-Baker L, Estilo A. Alpers DH, et al. Among authors: estilo a. Am J Kidney Dis. 2023 Mar;81(3):281-293.e1. doi: 10.1053/j.ajkd.2022.08.012. Epub 2022 Sep 30. Am J Kidney Dis. 2023. PMID: 36191725 Free article.

8

A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.

Shoaf SE, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D. Shoaf SE, et al. Among authors: estilo a. Clin J Am Soc Nephrol. 2020 May 7;15(5):643-650. doi: 10.2215/CJN.08170719. Epub 2020 Apr 2. Clin J Am Soc Nephrol. 2020. PMID: 32241780 Free PMC article.

9

Hemodynamic and catecholamine changes after administration of naloxone.

Estilo AE, Cottrell JE. Estilo AE, et al. Anesth Analg. 1982 Apr;61(4):349-53. Anesth Analg. 1982. PMID: 7199852

10

Naloxone, hypertension, and ruptured cerebral aneurysm.

Estilo AE, Cottrell JE. Estilo AE, et al. Anesthesiology. 1981 Apr;54(4):352. doi: 10.1097/00000542-198104000-00025. Anesthesiology. 1981. PMID: 7212343 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11 results

Search Page